Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of eribulin mesylate with trastuzumab in HER2-positive advanced or recurrent breast cancer
jRCT2080221578Phase 1
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin and trastuzumab in breast cancer, sponsored by Eisai Co., Ltd.
02
Drugs
eribulintrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221578.